Last edition
News about " Ianalumab "
Novartis Advances Ianalumab Toward Approval for Sjogren's Disease After Phase III Success
Novartis has reported positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjogren's disease.
Ianalumab | 11/08/2025 | By Dineshwori | 133
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members